Novel Methodology for Non-Fluoroscopic Wire Visualization During Pulsed Field Ablation for the Treatment of Atrial Fibrillation
We describe a novel approach for non-fluoroscopic wire visualization using EAM during PFA. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Ashraf Alzahrani, Peter Farjo, Michael Powers, Denice Hodgson-Zingman, E. Steven Bailin, Paari Dominic Source Type: research
Lb-469804-04 long-term safety and effectiveness after paroxysmal atrial fibrillation pulsed field ablation from the u.s. multicenter admire study
A novel variable loop pulsed field ablation (PFA) catheter integrated with an electroanatomical mapping (EAM) system was studied in the multicenter single-arm FDA IDE pivotal study, admIRE (NCT05293639), to treat paroxysmal AF (PAF). (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Vivek Y. Reddy, Hugh Calkins, Moussa Mansour, Oussama M. Wazni, Luigi Di Biase, Marwan M. Bahu, David W. Newton, Christopher F. Liu, William H. Sauer, Sandeep Goyal, Vivek Iyer, Devi G. Nair, Charles A. Athill, Ayman A. Hussein, S. Patrick Whalen, Daniel Source Type: research
Lb-469804-03 real world data collection in subjects treated with the farapulse pulsed field ablation system (faradise)
Pulsed field ablation (PFA), a non-thermal ablation modality, has recently demonstrated non-inferiority to thermal ablation for the treatment of paroxysmal atrial fibrillation (AF). The favorable safety profile and clinical efficiency has driven wide-scale adoption of PFA. The FARADISE global registry seeks to capture the real-world use of the pentaspline PFA catheter and characterize long-term clinical outcomes. As FARADISE enrollment is close to ending, we report on the acute outcome data. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Lucas V. Boersma, Gabor Szeplaki, Ignacio Garcia-Bolao, Michael Efremidis, Antonio Dello Russo, Stephan Willems, Haris M. Haqqani, Estelle Gandjbakhch, Nandor Szegedi, Nele Cielen, Madeline Johnson, Elizabeth Albrecht, Johan M. Vijgen Source Type: research
Lb-469804-02 long-term outcomes in long standing persistent atrial fibrillation following catheter or thoracoscopic surgical ablation using continuous monitoring: 3-year follow-up of the casa-af randomised controlled trial
CASA-AF (NCT02755688) was the first randomised controlled trial with continuous cardiac monitoring (CCM) comparing catheter (CA) and surgical (SA) ablation in de novo long-standing persistent atrial fibrillation (LSPAF). (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Vennela Boyalla, Shouvik Haldar, Habib Khan, Ines Kralj-Hans, Winston Banya, Joanne Lord, Anitha Gnanasekar, Toufan Bahrami, Anthony Desouza, Jonathan Clague, Darrel P. Francis, Wajid Hussain, Julian W. Jarman, David G. Jones, Zhong Chen, Neeraj Mediratta Source Type: research
Lb-469804-01 a randomized controlled trial of a lattice-tip mapping and ablation system with radiofrequency and pulsed field energy for treating persistent atrial fibrillation
SPHERE Per-AF (NCT05120193) is the first randomized controlled trial (RCT) to treat persistent atrial fibrillation (perAF) using either a wide footprint focal pulsed field (PF) and radiofrequency (RF) catheter or conventional RF ablation catheter with contact force sensing. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Elad Anter, Moussa Mansour, Devi G. Nair, Dinesh Sharma, Tyler L. Taigen, Petr Neuzil, Erich L. Kiehl, Josef Kautzner, Jose Osorio, Stavros Mountantonakis, Andrea Natale, John D. Hummel, Anish K. Amin, Usman R. Siddiqui, Doron Harlev, Paul Hultz, Shufeng Source Type: research
Lb-469805-01 tailored cardiac ablation procedure for persistent atrial fibrillation guided by artificial intelligence: the tailored-af randomized clinical trial
While pulmonary vein isolation (PVI) remains the cornerstone ablation procedure for paroxysmal atrial fibrillation (AF), the optimal procedure for persistent and long-standing persistent AF patients remains elusive. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Isabel Deisenhofer, Jean-Paul Albenque, Sonia Busch, Edouard Gitenay, Stavros Mountantonakis, Antoine Roux, Jerome Horvilleur, Bab é Bakouboula, Saumil R. Oza, Selim Abbey, Guillaume Théodore, Antoine Lepillier, Yves Guyomar, Francis Bessiere, Paola Mil Source Type: research
Lb-469809-04 safety and effectiveness of pulsed field ablation for atrial fibrillation in patients with heart failure: a manifest-pf registry sub-analysis
Atrial fibrillation (AF) and heart failure (HF) coexist, increasing morbidity and mortality. RCTs have shown improved clinical outcomes following AF ablation in HF patients with reduced EF. Pulsed-field ablation (PFA) preferentially targets myocardial tissue but its outcomes in HF is unknown. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Mohit K. Turagam, Petr Neuzil, Boris Schmidt, Tobias Reichlin, Kars Neven, Andreas Metzner, Jim Hansen, Yuri Blaauw, Philippe Maury, Thomas Arentz, Philipp Sommer, Ante Anic, Frederic Anselme, Serge Boveda, Tom Deneke, Stephan Willems, Pepijn van der Voor Source Type: research
Lb-469809-03 short- and long-term clinical outcomes of radiofrequency catheter ablation in paroxysmal atrial fibrillation: results from the prospective multicenter real-af registry
The impact of contemporary techniques and technologies to optimize ablation delivery, reduce fluoroscopy use, and improve clinical outcomes using radiofrequency catheter ablation (RF-CA) for paroxysmal atrial fibrillation (PAF) has not been assessed in systematic, large, prospective, multicenter registries. We aimed to assess the contemporary real-world practice approach, procedural and long-term clinical outcomes of RF-CA for PAF through a large prospective multicenter registry. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Paul C. Zei, Jose Osorio, Andr és F. Miranda-Arboleda, Joshua R. Silverstein, Saumil R. Oza, Anthony R. Magnano, Jorge Romero, Carlos D. Matos, Carolina Hoyos, Fernando Moreno, Daniela Hincapie Tabares, Anil Rajendra, Gustavo X. Morales, Alexandru I. Cos Source Type: research
Lb-469809-01 mediterranean diet enriched with extra-virgin olive oil reduced risk of tachyarrhythmia recurrence after atrial fibrillation ablation: the predimar trial
AF ablation has limited success. The PREDIMED trial showed that a Mediterranean diet(MeDiet) enriched with extra-virgin olive oil (EVOO) reduces incidental AF. The PREDIMAR trial assessed the effect of this dietary pattern on arrhythmia recurrence after ablation. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Maria T. Barrio-Lopez, Miguel Angel Martinez Gonzalez, Jesus Almendral, Pablo Ramos Ardanaz, Luis Tercedor, Jose L. Iba ñez Criado, Leticia Goni, Victor de la O, Ignacio Garcia-Bolao, Rosa Macias, Alicia Ibañez Criado, Miguel Ruiz-Canela Source Type: research
Lb-469807-05 outcomes with and without oral anticoagulation in patients with prior stroke and device-detected atrial fibrillation: the noah-afnet 6 trial
Patients with a prior stroke are at high risk of recurrent strokes. In patients with ECG-documented atrial fibrillation (AF), anticoagulation reduces subsequent strokes. Detection of short and rare episodes of atrial fibrillation using implanted devices (device-detected AF, DDAF) is common in patients with a prior stroke and these patients are often treated with an anticoagulant when DDAF is detected. Data on the effectiveness and safety of oral anticoagulation in patients a prior stroke and DDAF but no ECG-documented AF are lacking. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Hans Diener, Gregory Lip, Julius Nikorowitsch, Nina Becher, Carina Blomstr öm-Lundqvist, A. John Camm, Gregory Chlouverakis, Andreas Goette, Ulrich Schotten, Emmanuel Simantirakis, Tobias Toennis, Panos Vardas, Antonia Zapf, Susanne Sehner, Renate B. Sch Source Type: research
Lb-469807-04 efficacy and safety of apixaban versus aspirin according to cha2ds2-vasc score in patients with subclinical atrial fibrillation in artesia
ARTESiA showed that apixaban, compared to aspirin, significantly reduced stroke or systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation (SCAF). To better inform benefit-to-risk decision-making for the use of apixaban, we evaluated the benefits and hazards of apixaban according to baseline CHA2DS2-VASc score. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Jeffrey S. Healey, Christopher Granger, William F. McIntyre, Marco Alings, Daniel Wojdyla, Chinthanie Ramasundarahettige, Lena Rivard, Dan Atar, David H. Birnie, Giuseppe Boriani, Guy Amit, Peter Leong-Sit, Claus H. Rinne, Gabor Duray, Michael R. Gold, St Source Type: research
2023 Cardiac Society of Australia and New Zealand Expert Position Statement on Catheter and Surgical Ablation for Atrial Fibrillation
Catheter ablation for atrial fibrillation (AF) has increased exponentially in many developed countries, including Australia and New Zealand. This Expert Position Statement on Catheter and Surgical Ablation for Atrial Fibrillation from the Cardiac Society of Australia and New Zealand (CSANZ) recognises healthcare factors, expertise and expenditure relevant to the Australian and New Zealand healthcare environments including considerations of potential implications for First Nations Peoples. The statement is cognisant of international advice but tailored to local conditions and populations, and is intended to be used by elect...
Source: Heart, Lung and Circulation - May 2, 2024 Category: Cardiology Authors: Peter M. Kistler, Prash Sanders, John V. Amarena, Chris R. Bain, Karin M. Chia, Wai-Kah Choo, Adam T. Eslick, Tanya Hall, Ingrid K. Hopper, Emily Kotschet, Han S. Lim, Liang-Han Ling, Rajiv Mahajan, Silvana F. Marasco, Mark A. McGuire, Alex J. McLellan, R Tags: Position Statement Source Type: research
Apixaban Reduces Risk of Stroke or Systemic Embolism in Subclinical AF
Dr. Watson
Clinical question: Does oral anti-coagulation reduce stroke or systemic embolism risk in subclinical atrial fibrillation (AF)?
Background: Studies have shown an increased risk of stroke and systemic embolism in subclinical AF (short, asymptomatic episodes detected by permanent pacemakers and implantable cardiac defibrillators). While oral anti-coagulation has a well-recognized role in the treatment of clinical AF, its role in subclinical AF is uncertain.
Study design: Randomized controlled trial
Setting: 247 clinical sites in 16 European and North American countries
Synopsis: The study included 4,012 patients w...
Source: The Hospitalist - May 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: Cardiology In the Literature Source Type: research
High Frequency of AF Recurrence in Hospitalized Patients with New-onset AF
Dr. Watson
Clinical question: What is the frequency of atrial fibrillation (AF) recurrence in patients with new-onset AF, detected while hospitalized for a noncardiac medical illness or surgery, that returns to sinus rhythm prior to discharge?
Background: AF is frequently detected for the first time in patients hospitalized for a noncardiac medical illness or surgery and may be considered a provoked and transient phenomenon (rather than a paroxysmal one) in these instances. The frequency of AF recurrence and appropriate medical management in this population is unclear.
Study design: Matched cohort study
Setting: Three aca...
Source: The Hospitalist - May 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: Cardiology In the Literature Source Type: research
Elevated cardiovascular risk and acute events in hospitalized colon cancer survivors: A decade-apart study of two nationwide cohorts
CONCLUSION: Colon cancer survivors hospitalized 10 years apart in the United States showed an increased CVD risk with an increased risk of acute cardiovascular events (stroke 28%, PE 47%, arrhythmia 41%, and cardiac arrest 63%). It is vital to regularly screen colon cancer survivors with concomitant CVD risk factors to curtail long-term cardiovascular complications.PMID:38689632 | PMC:PMC11056864 | DOI:10.5306/wjco.v15.i4.548 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Rupak Desai Avilash Mondal Vivek Patel Sandeep Singh Shaylika Chauhan Akhil Jain Source Type: research
